 |
 |
 |
|
 |
| Saturday, May 30 |
|
|
|
|
|
| Saturday, May 30 |
9 a.m.-4 p.m.
11 a.m.-5 p.m.
1 p.m.-5 p.m.
7 p.m.-10 p.m.
IS2. Depression as a Risk Factor for Cardiovascular and Cerebrovascular Disease: Emerging Data and Clinical Perspectives Supported by SmithKline Beecham Pharmaceuticals
A. The Clinical and Medical Management of Depressed Patients With Ischemic Heart Disease Christopher O'Connor, M.D.
B. Are Platelets the Link Between Depression and Ischemic Heart Disease? Charles B. Nemeroff, M.D.
C. Depression as a Contributing Factor in Cerebrovascular Disease K. Ranga Rama Krishnan, M.D.
D. Heart Rate Variability in Depressive and Anxiety Disorders Jack M. Gorman, M.D.
E. Considerations for the Use of Antidepressants in Patients With Ischemic Heart Disease Steven P. Roose, M.D.
IS3. Management of Iatrogenic Sexual Dysfunction Supported by GlaxoWellcome Inc.
A. Etiology and Incidence R. Taylor Segraves, M.D.
B. Assessment of Sexual Functioning Anita L.H. Clayton, M.D.
C. Management of SRI-Induced Sexual Dysfunction Adam K. Ashton, M.D.
D. SSRI's in Premature Ejaculation and Paraphilias Richard Balon, M.D.
IS4. Cognition in Schizophrenia: The New Therapeutic Goal Supported by Pfizer U.S. Pharmaceuticals
A. Dimensions of Cognitive Dysfunction in Schizophrenia: The Kraepelinian Legacy Philip D. Harvey, Ph.D.
B. Cortical Circuitry and Cognition in Schizophrenia David A. Lewis, M.D.
C. Functional MRI Studies of Cognitive Function in Schizophrenia Daniel R. Weinberger, M.D.
D. Effect of Antipsychotic Drugs on Cognition in Schizophrenia Herbert Y. Meltzer, M.D.
E. Cognitive Impairment and Psychopathology as Determinants of Ability to Work in Schizophrenia Susan R. McGurk, Ph.D.
IS5. OCD Subtypes: From Clinical to Molecular Genetics Supported by Solvay Pharmaceuticals Inc. and Pharmacia & Upjohn Company Inc.
A. Phenotypic Components of OCD David Pauls, Ph.D.
B. Are OCD Spectrum Disorders Different Phenotypes of OCD? Eric Hollander, M.D.
C. OCD and Schizophrenia: Diagnostic and Treatment Considerations Joseph Zohar, M.D.
D. Molecular Genetics of OCD and Response to SRI's James L. Kennedy, M.D.
E. Autoimmunity and OCD Mark H. Rapaport, M.D.
IS6. Practical Approaches to the Treatment of Psychoses in the Elderly Supported by Abbott Laboratories
A. Chronic and Late-Onset Psychotic Disorders Ira R. Katz, M.D.
B. Organic Disorders With Psychotic Features in the Elderly Jeffrey L. Cummings, M.D.
C. Treatment Options and Practical Issues for Elderly Patients With Psychoses Pierre N. Tariot, M.D.
D. Psychotic Disorders Among Patients in Long-Term-Care Facilities Barry W. Rovner, M.D.
E. Nonpharmacologic Approaches in Managing Elderly Patients With Psychoses Soo Borson, M.D.
IS7. Mood Disorders in Schizophrenia: United States and European Perspectives Supported by the International Academy for Biomedical and Drug Research
A. Depressive Symptomatology in Schizophrenia: Comorbid Disorders or Negative Symptoms? Lewis L. Judd, M.D.
B. The Interface Between Bipolar and Schizophrenic Disorders: The United States Approach Hagop S. Akiskal, M.D.
C. The Interface Between Bipolar and Schizophrenic Disorders: The European Approach Helmut Beckmann, M.D.
D. New Therapeutic Approaches in the Management of Mood Disorders in Schizophrenia W. Wolfgang Fleischhacker, M.D.
E. New Therapeutic Approaches in the Management of Mood Disorders in Schizophrenia: The United States Perspective William T. Carpenter Jr., M.D.
F. The Use of New Antipsychotics in the Treatment of Schizoaffective Disorder Mario Maj, M.D.
IS8. Novel Antipsychotics: Use in Nonpsychotic Disorders Across the Life Cycle Supported by Janssen Pharmaceutica and Research Foundation
A. Novel Antipsychotics in Children and Adolescents Herman A. Tolbert, M.D.
B. Novel Antipsychotics in Personality Disorders Larry J. Siever, M.D.
C. Efficacy of Novel Antipsychotics in Basal Ganglia Disorders Henry A. Nasrallah, M.D.
D. Role of Novel Antipsychotics in Treatment of Mood Disorders Donna A. Wirshing, M.D.
E. Use of Atypical Antipsychotics in Dementia and Delirium Prakash S. Masand, M.D.
IS9. Estrogen Enhancement of Mood and Memory in Postmenopausal Women Supported by Wyeth-Ayerst Laboratories
A. Estrogens and Synapses: Basic Neurobiology of Ovarian Steroids Bruce S. McEwen, Ph.D.
B. Sexual Dimorphism, Memory, and Menopause Marjorie L. Shuer, M.D.
C. Estrogen and Cognition in Postmenopausal Women Barbara B. Sherwin, Ph.D.
D. Hormone-Replacement Therapy: Cognition and Alzheimer's Dementia Uriel Halbreich, M.D.
E. Practical Implications of Hormone-Replacement Therapy: Using Natural Hormones Joel T. Hargrove, M.D.